Please do not leave this page until complete. This can take a few moments.
Federal regulators formally rejected Genzyme’s multiple sclerosis (MS) treatment over concerns about trial design and potentially serious side effects, the Cambridge-based drug maker said Monday.
Genzyme said it strongly disagrees with the U.S. Food and Drug Administration’s conclusion and plans to appeal the agency’s decision.
“We are extremely disappointed with the outcome of the review and the implications for patients in the U.S. suffering with multiple sclerosis who remain in need of alternative therapies to manage a devastating disease,” said David Meeker, president and CEO of Genzyme, which has facilities in Northborough and Framingham.
The decision follows unfavorable reviews from FDA staff in November, who found Lemtrada increases the risk of autoimmune and thyroid diseases such as diabetes and cancer while failing to control for bias in its demonstration of clinical benefits.
The FDA asked Genzyme to conduct new clinical trials of Lemtrada using different designs and methods, which could take at least another year.
As part of French drug maker Sanofi’s $20.1 billion acquisition of Genzyme in 2011, Sanofi agreed to reward former Genzyme shareholders if Lemtrada achieved certain milestones. Genzyme announced Monday that it expects to miss a March 31 deadline for FDA approval of Lemtrada, which would have triggered one of those payments.
The announcement doesn’t appear to have hurt Sanofi’s stock price, which has climbed 1.2 percent from $52.80 to $53.41 since the market opened Monday.
Lemtrada has been approved for use in 30 other counties, including Australia, Canada and all of the European Union.
Read more
Stay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Sign upWorcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
SubscribeWorcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
See Digital EditionStay connected! Every business day, WBJ Daily Report will be delivered to your inbox by noon. It provides a daily update of the area’s most important business news.
Worcester Business Journal provides the top coverage of news, trends, data, politics and personalities of the Central Mass business community. Get the news and information you need from the award-winning writers at WBJ. Don’t miss out - subscribe today.
Worcester Business Journal presents a special commemorative edition celebrating the 300th anniversary of the city of Worcester. This landmark publication covers the city and region’s rich history of growth and innovation.
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments